Welcome to our dedicated page for C4 Therapeutics news (Ticker: CCCC), a resource for investors and traders seeking the latest updates and insights on C4 Therapeutics stock.
C4 Therapeutics, Inc. reports developments tied to its clinical-stage targeted protein degradation business, including oncology programs designed with its TORPEDO® platform. Recurring company updates cover cemsidomide, an oral IKZF1/3 degrader being studied in relapsed/refractory multiple myeloma, as well as broader degrader-medicine research intended to address disease-causing proteins.
Company news also includes collaboration activity, such as its Roche agreement for degrader-antibody conjugates, along with clinical disclosures, operating and financial results, conference participation, equity inducement grants, and other governance matters under Nasdaq rules.
C4 Therapeutics (Nasdaq: CCCC) approved an inducement grant of non-qualified stock options to purchase 85,480 shares of common stock for one new employee, effective May 18, 2026.
The options’ exercise price equals the closing stock price on the grant date and vest over four years, subject to continued employment.
C4 Therapeutics (Nasdaq: CCCC) reported first quarter 2026 revenue of $6.2 million, down from $7.2 million a year earlier, and a net loss of $25.1 million or $0.20 per share.
The company advanced multiple myeloma degrader cemsidomide with ongoing Phase 2 MOMENTUM and Phase 1b elranatamab combination trials and plans another Phase 1b combo study in 1H 2027. A new Roche collaboration on degrader-antibody conjugates brought a $20 million upfront payment. Cash, cash equivalents and marketable securities were $268.3 million on March 31, 2026, with funding expected to last through year-end 2028. C4 Therapeutics decided not to advance CFT8919 for EGFR-mutated NSCLC outside Greater China.
C4 Therapeutics (Nasdaq: CCCC) expanded its long-term partnership with Roche on April 9, 2026 to discover and develop degrader-antibody conjugates (DACs) for oncology. The agreement covers two collaboration-exclusive programs, an option for a third target, and combines C4T's TORPEDO platform with Roche's ADC expertise.
Financial terms include a $20 million upfront payment, additional payment if Roche exercises a third-target option, near-term discovery milestones, eligibility for over $1 billion in discovery, regulatory and commercial milestones, and tiered royalties on future sales.
C4 Therapeutics (Nasdaq: CCCC) announced the first patient has been dosed in a Phase 1b trial of oral cemsidomide plus dexamethasone with FDA-approved elranatamab (ELREXFIO) for relapsed/refractory multiple myeloma.
The open-label, multicenter study will enroll up to 54 patients, test 50/75/100 µg cemsidomide doses, assess safety/tolerability as the primary endpoint, and aims to report Phase 1b data in mid-2027. Pfizer supplies elranatamab at no cost per the collaboration.
C4 Therapeutics (Nasdaq: CCCC) announced an inducement non-qualified stock option grant of 85,480 shares to one new employee, approved March 9, 2026. The exercise price equals the closing market price on the grant date. Vesting: four years with 25% after year one, then 36 monthly installments.
The grant was made as a material inducement under Nasdaq Listing Rule 5635(c)(4) and is subject to continued employment through each vesting date.
C4 Therapeutics (Nasdaq: CCCC) reported 2025 results and program progress on Feb 26, 2026. Key items: cemsidomide moved into a Phase 2 MOMENTUM trial with first patient dosed and a recommended Phase 2 dose of 100 µg. Cash, cash equivalents and marketable securities were $297.1M at Dec 31, 2025, providing runway to the end of 2028. Company raised $125M in October 2025 and earned a $2M Biogen milestone; Phase 1b combo trial with elranatamab is on track for Q2 2026.
C4 Therapeutics (Nasdaq: CCCC) announced management will participate in two March 2026 healthcare conferences with live webcasts available for investors. Management will present at the TD Cowen conference on March 3, 2026 at 11:50 AM ET and participate in Barclays on March 10, 2026 at 8:00 AM ET.
Webcasts will stream on the company’s Investor website, with archived replays available for about 90 days after each event.
C4 Therapeutics (Nasdaq: CCCC) dosed the first patient in the Phase 2 MOMENTUM trial of cemsidomide, an oral IKZF1/3 degrader, combined with dexamethasone for relapsed/refractory multiple myeloma.
The open-label, single-arm study will enroll ~100 patients at the 100 µg dose (14 days on/14 days off dosing) with overall response rate as the primary endpoint. Enrollment is expected to complete in Q1 2027, and a Phase 1b combination trial with elranatamab is on track to initiate in Q2 2026.
C4 Therapeutics (Nasdaq: CCCC) announced an inducement grant of non-qualified stock options covering 162,880 shares to one new employee, approved by independent directors on February 9, 2026.
The options have an exercise price equal to the closing share price on the grant date and vest over four years (25% after one year, then monthly over three years), subject to continued employment.
C4 Therapeutics (NASDAQ: CCCC) announced that company management will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 in New York.
The fireside chat is scheduled for Wednesday, February 11, 2026 at 11:30 AM ET. A live webcast will be available on the company’s Investors website, with an archived replay accessible for approximately 90 days.